Observes people with advanced melanoma in Spain since 2018
Part of Cancer, Skin clinical trials.
This observational study collects information about people with advanced (stage III/IV) melanoma, including cases that are metastatic or cannot be removed by surgery. It may help improve understanding of how melanoma behaves and how it’s being treated across Spain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (legal age).
- You were diagnosed with stage III advanced, metastatic, or unresectable melanoma for the first time after January 8, 2018.
- Your melanoma was metastatic or unresectable at first diagnosis, or your first relapse/remain-unremovable cancer happened after January 8, 2018 after earlier localized melanoma was fully removed.
- You agree to take part by signing the informed consent form (ICF).
- You can sign the study consent only once, at one participating center.
- You can be treated at other hospitals, but you must still meet the diagnosis timing rules above.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This study follows adults with certain melanoma stages to better understand the disease over time. You may be asked to share tissue samples (if available) so researchers can study tumor biology and track outcomes.
This study looks at how people with stage IV melanoma take part in research. It helps doctors understand what works best for patients like you.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
Hear when a new Melanoma Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.